115 related articles for article (PubMed ID: 29620279)
1. Impact of RUNX2 gene silencing on the gemcitabine sensitivity of p53‑mutated pancreatic cancer MiaPaCa‑2 spheres.
Sang M; Nakamura M; Ogata T; Sun D; Shimozato O; Nikaido T; Ozaki T
Oncol Rep; 2018 Jun; 39(6):2749-2758. PubMed ID: 29620279
[TBL] [Abstract][Full Text] [Related]
2. Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.
Ozaki T; Nakamura M; Ogata T; Sang M; Yoda H; Hiraoka K; Sang M; Shimozato O
Oncotarget; 2016 Nov; 7(44):71937-71950. PubMed ID: 27713122
[TBL] [Abstract][Full Text] [Related]
3. Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations.
Ozaki T; Yu M; Yin D; Sun D; Zhu Y; Bu Y; Sang M
BMC Cancer; 2018 Mar; 18(1):309. PubMed ID: 29558908
[TBL] [Abstract][Full Text] [Related]
4. Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death.
Sugimoto H; Nakamura M; Yoda H; Hiraoka K; Shinohara K; Sang M; Fujiwara K; Shimozato O; Nagase H; Ozaki T
Cell Death Dis; 2015 Oct; 6(10):e1914. PubMed ID: 26469963
[No Abstract] [Full Text] [Related]
5. Depletion of runt-related transcription factor 2 (RUNX2) enhances SAHA sensitivity of p53-mutated pancreatic cancer cells through the regulation of mutant p53 and TAp63.
Ogata T; Nakamura M; Sang M; Yoda H; Hiraoka K; Yin D; Sang M; Shimozato O; Ozaki T
PLoS One; 2017; 12(7):e0179884. PubMed ID: 28671946
[TBL] [Abstract][Full Text] [Related]
6. Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death.
Sugimoto H; Nakamura M; Yoda H; Hiraoka K; Shinohara K; Sang M; Fujiwara K; Shimozato O; Nagase H; Ozaki T
Cell Death Discov; 2015; 1():15010. PubMed ID: 27551445
[TBL] [Abstract][Full Text] [Related]
7. Improvement of gemcitabine sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells by RUNX2 depletion-mediated augmentation of TAp73-dependent cell death.
Nakamura M; Sugimoto H; Ogata T; Hiraoka K; Yoda H; Sang M; Sang M; Zhu Y; Yu M; Shimozato O; Ozaki T
Oncogenesis; 2016 Jun; 5(6):e233. PubMed ID: 27294865
[TBL] [Abstract][Full Text] [Related]
8. Runt-related transcription factor 2 attenuates the transcriptional activity as well as DNA damage-mediated induction of pro-apoptotic TAp73 to regulate chemosensitivity.
Ozaki T; Sugimoto H; Nakamura M; Hiraoka K; Yoda H; Sang M; Fujiwara K; Nagase H
FEBS J; 2015 Jan; 282(1):114-28. PubMed ID: 25331851
[TBL] [Abstract][Full Text] [Related]
9. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
Nakahira S; Nakamori S; Tsujie M; Takahashi Y; Okami J; Yoshioka S; Yamasaki M; Marubashi S; Takemasa I; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
Int J Cancer; 2007 Mar; 120(6):1355-63. PubMed ID: 17131328
[TBL] [Abstract][Full Text] [Related]
10. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
Jakstaite A; Maziukiene A; Silkuniene G; Kmieliute K; Gulbinas A; Dambrauskas Z
World J Gastroenterol; 2015 Dec; 21(46):13004-19. PubMed ID: 26675757
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response.
Takahara A; Koido S; Ito M; Nagasaki E; Sagawa Y; Iwamoto T; Komita H; Ochi T; Fujiwara H; Yasukawa M; Mineno J; Shiku H; Nishida S; Sugiyama H; Tajiri H; Homma S
Cancer Immunol Immunother; 2011 Sep; 60(9):1289-97. PubMed ID: 21607557
[TBL] [Abstract][Full Text] [Related]
12. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
[TBL] [Abstract][Full Text] [Related]
13. Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro.
Liu DL; Bu H; Li H; Chen H; Guo HC; Wang ZH; Tong HF; Ni ZL; Liu HB; Lin SZ
Int J Oncol; 2012 Apr; 40(4):1049-57. PubMed ID: 22159556
[TBL] [Abstract][Full Text] [Related]
14. Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.
Shen Y; Pan Y; Xu L; Chen L; Liu L; Chen H; Chen Z; Meng Z
Tumour Biol; 2015 Jun; 36(6):4525-34. PubMed ID: 25722110
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.
Liu S; Ge Y; Wang T; Edwards H; Ren Q; Jiang Y; Quan C; Wang G
Oncol Rep; 2017 Jun; 37(6):3377-3386. PubMed ID: 28440428
[TBL] [Abstract][Full Text] [Related]
16. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
Brandes F; Schmidt K; Wagner C; Redekopf J; Schlitt HJ; Geissler EK; Lang SA
BMC Cancer; 2015 Feb; 15():71. PubMed ID: 25884642
[TBL] [Abstract][Full Text] [Related]
17. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
18. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
[TBL] [Abstract][Full Text] [Related]
19. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
[TBL] [Abstract][Full Text] [Related]
20. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
Pan MR; Hsu MC; Luo CW; Chen LT; Shan YS; Hung WC
Oncotarget; 2016 Sep; 7(38):61136-61151. PubMed ID: 27531902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]